Salvatore Brugaletta - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Salvatore Brugaletta's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Salvatore Brugaletta
Verified
Editor-in-Chief, PCR Online
Barcelona
Beats
Entrepreneur building Health and WellnessMental Health success stories.
Household appliances, mother and baby, finance
Content
Percutaneous coronary treatment with Bioadaptor implant vs drug-eluting stent : 2-year outcomes from BIOADAPTOR RCT
By Giovanni Occhipinti, Salvatore Brugaletta| PCR Online@ Selected in JACC: Cardiovascular Interventions by G. Occhipinti , S. Brugaletta At two-year follow-up, the use of sirolimus-eluting cobalt-chromium DynamX Drug Eluting Coronary Bioadaptor System (Elixir Medical Corporation) resulted in fewer target lesion failure (TLF) compared with the Resolute Onyx contemporary drug-eluting stent. References Authors Shigeru Saito, Johan Bennett, Holger M.
By Francisco Rafael Jimenez-Trinidad, Manel Sabaté, Salvatore Brugaletta, Sergi Calvo-Gomez| MDPI@ All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Percutaneous coronary treatment with Bioadaptor implant vs drug-eluting stent : 2-year outcomes from BIOADAPTOR RCT
By Giovanni Occhipinti, Salvatore Brugaletta| PCR Online@ Selected in JACC: Cardiovascular Interventions by G. Occhipinti , S. Brugaletta At two-year follow-up, the use of sirolimus-eluting cobalt-chromium DynamX Drug Eluting Coronary Bioadaptor System (Elixir Medical Corporation) resulted in fewer target lesion failure (TLF) compared with the Resolute Onyx contemporary drug-eluting stent. References Authors Shigeru Saito, Johan Bennett, Holger M.
Company Info
PCR Online
Barcelona, Spain